Hary Katz, MD
Pediatric Allergy/Immunology · Jacksonville, FLNPI 1053322586
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,055 of the $67,379 with a category attached, or 71.3%. AstraZeneca accounts for 74.9% of it on its own, with 27 other manufacturers making up the rest. 2025 is the largest year on record at $19,574, more than ten times the $529 reported in 2019.
Across 265 payments — averaging $254.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$50K
- ARS Pharmaceuticals Operations, Inc.$5K
- CSL Behring$5K
- Sanofi$2K
- Pfizer$2K
- Aimmune Therapeutics, Inc.$539
- plus $2K from 22 others
What the payments were for
- Consulting fees$8,71013%
- Speaking & faculty fees$48,05571%
- Travel & lodging$4,8607%
- Food & beverage$5,6818%
- Education$730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 118 | $50,478 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $5,178 |
| CSL Behring | 11 | $5,005 |
| Sanofi | 19 | $2,335 |
| Pfizer | 14 | $1,764 |
| Aimmune Therapeutics, Inc. | 4 | $539 |
| Regeneron Healthcare Solutions, Inc. | 20 | $530 |
| GSK | 19 | $434 |
| Pharming Healthcare, Inc. | 8 | $161 |
| Novartis | 9 | $146 |
| Ionis Pharmaceuticals, Inc. | 1 | $108 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $90 |
| Grifols USA, LLC | 4 | $81 |
| Genentech USA, Inc. | 5 | $78 |
| Incyte Corporation | 4 | $70 |
| Octapharma USA, Inc. | 3 | $61 |
| Amgen | 2 | $55 |
| Azurity Pharmaceuticals, Inc. | 2 | $41 |
| Kaleo, Inc. | 2 | $37 |
| Regeneron | 1 | $33 |
| ADMA Biomanufacturing LLC | 1 | $26 |
| Greer Laboratories, Inc. | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Alk-abello, Inc | 1 | $20 |
| Merck | 1 | $18 |
| Biocryst US Sales Co., LLC | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$67,379 in reported general payments places this provider in the 80th percentile of 30 pediatric allergy/immunology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $97,598 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $23,042 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $19,610 |
| Pulmicort FlexhalerBudesonide | 12 | $5,272 |
| Arnuity ElliptaFluticasone Furoate | 16 | $3,153 |
| Azelastine Hcl | 70 | $2,857 |
| Epinephrine | 13 | $2,287 |
| Ipratropium Bromide | 40 | $1,239 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $991 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $984 |
| Fluticasone Propionate | 37 | $938 |
| Montelukast Sodium | 79 | $877 |
| Levocetirizine Dihydrochloride | 15 | $415 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $122 |
| Prednisone | 13 | $34 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $90 | $97,59812 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $434 | $45,80571 claims |
| AstraZenecaPulmicort Flexhaler | $50,478 | $5,27212 claims |
| Hikma Pharmaceuticals USAEpinephrine | $21 | $2,28713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 30 pediatric allergy/immunology providers in Florida.
Other pediatric allergy/immunology in Jacksonville
- Sharon LeonardJacksonville$8K
- Jacob SchrumJacksonville$424
- Shajitha MelethilJacksonville$423
- Ejaz YousefJacksonville$195
- Mark BallowTampa$324K
- Vivian Hernandez-TrujilloMiami Lakes$285K
- Jolan WalterSt Petersburg$232K
- Jennifer LeidingOrlando$214K
- Panida SriaroonSaint Petersburg$70K
- Jonathan MalkaNorth Miami Beach$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.